Protea buys CRO vivoPharm for preclinical expertise

West Virginia bioanalytics outfit Protea Biosciences has acquired preclinical researcher vivoPharm to expand in the world of early-stage oncology development. VivoPharm specializes in crafting tumor models and cell lines for cancer research, working with pharma and biotech on preclinical studies. Protea, which focuses on molecular information and R&D imaging, believes combining the two companies will create a unique presence on the market. Release

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

Analytica Laser has a novel system which the company touts as the industry's first dynamic tool to predict real-world health outcomes.

Genae's CEO says the transaction reflects recent focus on digital health and data-driven services.